Co-Authors
This is a "connection" page, showing publications co-authored by Raffaele Bruno and Fausto Baldanti.
Connection Strength
2.230
-
SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay. Clin Microbiol Infect. 2021 Jul; 27(7):1029-1034.
Score: 0.234
-
Low risk of SARS-CoV-2 transmission by fomites in real-life conditions. Lancet Infect Dis. 2021 05; 21(5):e112.
Score: 0.226
-
SARS-CoV-2 Virologic and Immunologic Correlates in Patients with Olfactory and Taste Disorders. Microorganisms. 2020 Jul 15; 8(7).
Score: 0.223
-
SARS-CoV-2 positivity in rectal swabs: implication for possible transmission. J Glob Antimicrob Resist. 2020 09; 22:754-755.
Score: 0.223
-
Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. Euro Surveill. 2020 06; 25(24).
Score: 0.221
-
Management of hepatitis C positive patients undergoing active treatment for malignancies: A position paper from the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Malattie Infettive e Tropicali (SIMIT). Semin Oncol. 2018 10; 45(5-6):259-263.
Score: 0.198
-
Correction to: Venous thromboembolism and COVID-19: a single center experience from an academic tertiary referral hospital of Northern Italy. Intern Emerg Med. 2021 Aug; 16(5):1153.
Score: 0.060
-
Systematic screening for SARS-CoV-2 in patients with hematological malignancies on active anticancer treatment in the outpatient setting. Leuk Lymphoma. 2021 12; 62(13):3311-3312.
Score: 0.060
-
Lung ultrasound presentation of COVID-19 patients: phenotypes and correlations. Intern Emerg Med. 2021 08; 16(5):1317-1327.
Score: 0.058
-
Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. Med (N Y). 2021 Mar 12; 2(3):281-295.e4.
Score: 0.058
-
EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int J Infect Dis. 2021 Mar; 104:315-319.
Score: 0.057
-
Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica. 2020 12 01; 105(12):2834-2840.
Score: 0.057
-
Venous thromboembolism and COVID-19: a single center experience from an academic tertiary referral hospital of Northern Italy. Intern Emerg Med. 2021 08; 16(5):1141-1152.
Score: 0.057
-
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatr. 2020 Sep 01; 174(9):882-889.
Score: 0.056
-
Setup of a Dedicated Coronavirus Intensive Care Unit: Logistical Aspects. Anesthesiology. 2020 07; 133(1):244-246.
Score: 0.056
-
Myocarditis in a 16-year-old boy positive for SARS-CoV-2. Lancet. 2020 06 27; 395(10242):e116.
Score: 0.056
-
Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol. Intern Emerg Med. 2020 08; 15(5):819-824.
Score: 0.055
-
Our recommendations for acute management of COVID-19. Crit Care. 2020 May 08; 24(1):207.
Score: 0.055
-
Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020 05; 22(5):911-915.
Score: 0.055
-
Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. J Med Virol. 2020 10; 92(10):1724-1727.
Score: 0.055
-
Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. Euro Surveill. 2020 04; 25(16).
Score: 0.055
-
Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. J Hosp Infect. 2020 Mar 19.
Score: 0.055